UBS (Lux) Equity SICAV - European Opportunity Unconstrained (EUR) (GBP hedged) Q-accRegister to Unlock Ratings |
Performance History | 30/06/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 9.5 | 26.2 | -15.8 | 7.7 | 13.8 | |
+/-Cat | - | - | - | - | - | |
+/-B’mrk | - | - | - | - | - | |
Category: Other Equity | ||||||
Category Benchmark: - |
Key Stats | ||
NAV 26/07/2024 | GBP 228.33 | |
Day Change | 0.60% | |
Morningstar Category™ | Other Equity | |
IA (formerly IMA) Sector | - | |
ISIN | LU1059394855 | |
Fund Size (Mil) 26/07/2024 | EUR 493.47 | |
Share Class Size (Mil) 26/07/2024 | GBP 5.11 | |
Max Initial Charge | 5.00% | |
Ongoing Charge 17/07/2024 | 1.10% |
Investment Objective: UBS (Lux) Equity SICAV - European Opportunity Unconstrained (EUR) (GBP hedged) Q-acc |
This actively managed sub-fund predominantly invests in equities, equity rights or other equity interests in companies domiciled or chiefly active in Europe. The UBS ESG consensus score is used to identify issuers/companies for the investment universe with strong environmental and social performance characteristics, or a strong sustainability profile. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Maximilian Anderl 23/07/2012 | ||
Jeremy Leung 01/04/2011 | ||
Inception Date 09/05/2014 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI Europe NR EUR | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for UBS (Lux) Equity SICAV - European Opportunity Unconstrained (EUR) (GBP hedged) Q-acc | 30/06/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk A/S Class B | Healthcare | 5.44 |
UBS (Irl) Inv Sel Eq Opp L/S € U-B | 4.86 | |
ASML Holding NV | Technology | 4.26 |
UBS (Irl) Inv Sel Eq Opp L/S I-B | 3.43 | |
Tryg A/S | Financial Services | 3.11 |
Increase Decrease New since last portfolio | ||
UBS (Lux) Equity SICAV - European Opportunity Unconstrained (EUR) (GBP hedged) Q-acc |